स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - levodopum, benserazidum - compresse - levodopum 200.000 mg, benserazidum 50.000 mg ut benserazidi hydrochloridum, hypromellosum, mannitolum, e 172 (rubrum), povidonum k 30, magnesii stearas, silica colloidalis hydrica, ricini oleum hydrogenatum, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 2.9 mg, pro compresso. - morbo di parkinson, delle gambe senza riposo-syndrom - synthetika

स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

zambon svizzera sa - safinamidum - compresse rivestite con film - safinamidum 50 mg ut safinamidi mesilas, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, coperta: hypromellosum, macrogolum 6000, kalii aluminii silicas, e 171, e 172 (rubrum) pro compresso obducto. - malattia di parkinson idiopatica - synthetika

स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

zambon svizzera sa - safinamidum - compresse rivestite con film - safinamidum 100 mg ut safinamidi mesilas, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, coperta: hypromellosum, macrogolum 6000, kalii aluminii silicas, e 171, e 172 (rubrum) pro compresso obducto. - malattia di parkinson idiopatica - synthetika

इटली - इतालवी - AIFA (Agenzia Italiana del Farmaco)

a. menarini industrie farmaceutiche riunite s.r.l. - pseudoefedrina, associazioni - pseudoefedrina, associazioni

स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

bial sa - opicaponum - capsule - opicaponum 50 mg, lactosum monohydricum 156 mg, amylum pregelificatum, carboxymethylamylum natricum a corresp. natrium 0.714 mg, magnesii stearas, matériel de la capsule: gelatina, e 127, e 132, e 171, encre: lacca, e 171, propylenglycolum, ammoniae solutio concentrata, simeticonum pro capsula. - il morbo di parkinson - synthetika

स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - benserazidum, levodopum - compresse - benserazidum 12.5 mg ut benserazidi hydrochloridum, levodopum 50 mg, natrii docusas, e 172 (rubrum), ethylcellulosum, silica colloidalis anhydrica, cellulosum microcristallinum, amylum pregelificatum, mannitolum, calcii hydrogenophosphas, crospovidonum, magnesii stearas, pro compresso corresp. natrium 0.00259 mg. - morbo di parkinson, delle gambe senza riposo-syndrom - synthetika

स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - benserazidum, levodopum - compresse - benserazidum 25 mg ut benserazidi hydrochloridum, levodopum 100 mg, natrii docusas, e 172 (rubrum), ethylcellulosum, silica colloidalis anhydrica, cellulosum microcristallinum, amylum pregelificatum, mannitolum, calcii hydrogenophosphas, crospovidonum, magnesii stearas, pro compresso corresp. natrium 0.00517 mg. - morbo di parkinson, delle gambe senza riposo-syndrom - synthetika

स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - benserazidum, levodopum - compresse - benserazidum 50 mg ut benserazidi hydrochloridum, levodopum 200 mg, natrii docusas, e 172 (rubrum), ethylcellulosum, silica colloidalis anhydrica, cellulosum microcristallinum, amylum pregelificatum, mannitolum, calcii hydrogenophosphas, crospovidonum, magnesii stearas, pro compresso corresp. natrium 0.01035 mg. - morbo di parkinson, delle gambe senza riposo-syndrom - synthetika

यूरोपीय संघ - इतालवी - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - morbo di parkinson - farmaci anti-parkinson - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

इटली - इतालवी - AIFA (Agenzia Italiana del Farmaco)

clinigen healthcare b.v. - glicopirronio - glicopirronio